Clinical Trial Based on the Use of Mononuclear Cells From Autologous Bone Marrow in Patients With Pseudoarthrosis

An estimated 10% of closed fractures and between 35-45% in cases of open fractures, are at risk of developing a delay in the process of consolidation or a complete failure of it (pseudoarthrosis) depending on location , severity of trauma on bone, soft tissue and vascular structures Some of these cases are refractory to all treatment methods available today, requiring numerous interventions with the potential risk for recurrent infections that they carry. For this reason, its treatment remains a challenge for the orthopedic surgeon.

Recent advances in knowledge of cellular and molecular biology related to the mechanism of bone repair and biomaterials science have been joined in a new discipline called tissue engineering, its implementation in clinical practice is being done so progressive.

Cell therapy based on the use of adult stem cells (MSCs) derived from autologous bone marrow, introduces new applications for the repair of fractures including pseudoarthrosis and avascular bone necrosis.

Its mechanism of action does not focus only on their local action, but also in the release of signaling molecules with autocrine and paracrine action through recruitment and activation of endogenous MSCs to osteoblastic differentiation and bone tissue regeneration.

On the other hand, the seeding of MSCs on biomaterials (natural or synthetic) is more effective, to facilitate adherence, proliferation and extracellular matrix production in the area where implanted.

Today, the investigators can say that there are experimental and clinical evidence supporting the effectiveness of the method.

The investigators have designed a phase II clinical trial to check the feasibility of this approach.

Inclusion criteria

• Pseudarthrosis of tibia established any cause with at least 9 months.
• The pseudarthrosis is not to show signs of healing in the last 3 months.
• The pseudarthrosis subsidiary should not be solely osteosynthesis treatment.
• Age between 18 and 75 years.
• Serology Human Immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) negative.
• Negative pregnancy test in women of childbearing age.
• Patient sufficient guarantees of adherence to protocol.
• Signature written informed consent before a witness

Exclusion criteria

• Systemic infection.
• Septic pseudoarthrosis.
• Insufficient skin coverage at the site of nonunion.
• Vascular insufficiency in the affected limb.
• Pathological fracture.
• Concomitant psychiatric or neurological disease.
• Concurrent or prior malignancy treated with chemotherapy over a period of less than 1 year.
• Concomitant severe disease not well controlled.
• Inclusion in other clinical trials.
• Inability to understand the informed consent